Outsourcing will be seen as being "instrumental" in the
eyes of healthcare and biopharma firms this year as the focus on
cost reduction continues to increase, according to a new report.
Product recalls in the UK due to health and safety concerns have
shot up to their highest level, with the rise in outsourcing to
China finger pointed for much of the blame.
As of next year Chinese pharmaceutical manufacturers will face a
tougher time gaining good manufacturing practice (GMP)
certification after the country's regulator signalled new and
stricter standards were on the way.
This week two sets of contract research organisations (CROs) have
announced plans to link arms in order to spread their reach further
into this increasingly globalised marketplace.
